The impact of adding optical coherence tomography in MS diagnostic criteria on the classification of tumefactive demyelination
Fiorella S. Guido(Mayo Clinic in Arizona), W. Oliver Tobin(Mayo Clinic in Arizona), Eoin P. Flanagan, Jeanette E. Eckel‐Passow(Mayo Clinic in Florida), Claudia F. Lucchinetti(Mayo Clinic in Arizona), Deena Tajfirouz(Anna Needs Neuroblastoma Answers), Kevin D. Chodnicki(Mayo Clinic), John J. Chen(Mayo Clinic), Paul A. Decker(Mayo Clinic in Florida), Mahboubeh Fereidan-Esfahani(Mayo Clinic in Arizona), B. Mark Keegan(Mayo Clinic in Arizona), Jan-Mendelt Tillema(Mayo Clinic), Sean J. Pittock(Mayo Clinic in Arizona), Orhun H. Kantarci(Istanbul University)
Cited by 1
Related Papers
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
|The Lancet|2004|3.2k
Revised diagnostic criteria for neuromyelitis optica
|Neurology|2006|2.6k
The spectrum of neuromyelitis optica
|The Lancet Neurology|2007|2.2k
Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis
|Annals of Neurology|2018|758